New vaccines may address need to protect newborns in the developing world

PHILADELPHIA -- In a new research study, two prototype oral vaccines have both been shown capable of inducing protection against a dangerous virus in newborn mice. If the new vaccines are able to do the same for human newborns, they might be able to address an important window of immunological vulnerability in the lives of infant children. Particularly in the developing world, where the threat of infectious diseases is generally greater than in the developed world, many lives might be saved with vaccines of this type.

The vaccines are based on human and chimpanzee adenoviruses that have been altered in the laboratory so that they are unable to replicate. In the current proof-of-principle study, the viruses were engineered to incorporate a gene from the rabies virus. Following oral administration of the vaccine, newborn mice developed antibodies that protected them from subsequent exposure to the rabies virus. By extension, the researchers say, the same vaccine strategy might also prove effective against other viral diseases, such as measles, viral respiratory infections, and viral diarrhea. A report on the study findings appears in the October 15 issue of the Journal of Immunology.

The potential significance of the new study lies in the effectiveness of the prototype vaccines in newborns. Although newborns are protected from most common viral infections immediately after birth by antibodies received from their mothers, these antibodies decline in the first weeks and months of life as the fledgling immune system grows in its capacity to generate its own antibody protections against viruses. Between the waning of maternal-antibody protection and the development of a fully functional immune system in the infant, a period of relatively poor defense against disease for infants is frequently seen. This is partly because the infant immune system is not yet sufficiently developed, but also because the maternal antibodies, while protecting the infant from inf

Contact: Franklin Hoke
The Wistar Institute

Page: 1 2 3

Related biology news :

1. Inadequate vaccines can help breed more vicious malaria strains
2. Researcher issues caution on live virus vaccines
3. Scientists learn how adjuvant makes vaccines effective
4. Thimerosal, found in childhood vaccines, can increase the risk of autism-like damage in mice
5. Botulinum toxin structure offers clues for vaccines/treatments
6. Gates Foundation commits $82.9 million to develop new tuberculosis vaccines
7. A link between thimerosal and the brain: Can vaccines affect central nervous system function?
8. WSU scientist part of study seeking vaccines to combat potential bioterrorist attack
9. Immune cells may help deliver cancer vaccines for children
10. Microgel polymer beads may provide general vehicle for vaccines, gene therapy
11. Bacterial viruses make cheap easy vaccines

Post Your Comments:

(Date:9/17/2019)... CITY (PRWEB) , ... September 17, 2019 , ... ... and a group of doctors, scientists and engineers from the Medical University of ... the results of their work to-date in creating a neuroprosthetic system as part ...
(Date:9/14/2019)... , ... September 13, 2019 , ... ... imaging Society (WMIS) focused on non-invasive real-time tracking of gene therapy and advances ... of five years (and most cases fatal) lysomal storage diseases (LSD) are among ...
(Date:9/8/2019)... Md. (PRWEB) , ... September ... ... biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell ... first human umbilical cord (hUC) MSC paired cell and media system designed ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... (PRWEB) , ... October 09, 2019 , ... ... 10th, groups of Montgomery County middle school and high school students have improved ... stressors, utilize relaxation techniques and physical fitness, and apply lifelong social/interpersonal, leadership, problem-solving ...
(Date:10/10/2019)... Ariz. (PRWEB) , ... October 10, 2019 , ... ... Pratia , the largest network of clinical research centers in Europe. All Pratia ... site network in Europe to become trained and certified as Virtual Trial Capable ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global leader ... announces that the U.S. Food and Drug Administration (FDA) has granted the company ... relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia continues ...
(Date:10/3/2019)... , ... October 01, 2019 , ... ... relax and reset itself, announced the midway point of its randomized research trial ... the study is to measure the efficacy of a non-invasive technology which compares ...
Breaking Biology Technology:
Cached News: